Suzanne L Topalian

14PUBLICATIONS
105CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Feb 03, 2025
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types.

Zhen Zeng, Tianbei Zhang, Jiajia Zhang

|Jan 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.

Shailender Bhatia, Suzanne L Topalian, William Sharfman

|Jan 24, 2025
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care.

Suzanne L Topalian, Drew M Pardoll

|Nov 21, 2024
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy.

Tracee L McMiller, Sepideh Besharati, Mark Yarchoan

|Nov 06, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Georgina V Long, James Larkin, Dirk Schadendorf

|Mar 05, 2024
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.

Shuming Chen, Tracee L McMiller, Abha Soni

Pageof 3

Frequent Collaborators

4 joint publications

Evan J Lipson

4 joint publications

Drew M Pardoll

3 joint publications

Janis Taube

2 joint publications

Paul Nghiem